Nothing Special   »   [go: up one dir, main page]

DK3175852T3 - Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande - Google Patents

Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande Download PDF

Info

Publication number
DK3175852T3
DK3175852T3 DK16192448.5T DK16192448T DK3175852T3 DK 3175852 T3 DK3175852 T3 DK 3175852T3 DK 16192448 T DK16192448 T DK 16192448T DK 3175852 T3 DK3175852 T3 DK 3175852T3
Authority
DK
Denmark
Prior art keywords
difluorolactam
compositions
conditions
related diseases
osteo
Prior art date
Application number
DK16192448.5T
Other languages
English (en)
Inventor
Stephen Douglas Barrett
Fred Lawrence Ciske
Joseph Michael Colombo
Gregory William Endres
Bradlee David Germain
Andriy Kornilov
James Bernard Kramer
Adam Uzieblo
Thomas Allen Owen
James Paul O'malley
Original Assignee
Cayman Chemical Co Inc
Myometrics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cayman Chemical Co Inc, Myometrics Llc filed Critical Cayman Chemical Co Inc
Application granted granted Critical
Publication of DK3175852T3 publication Critical patent/DK3175852T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0015Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0042Materials resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/02Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/12Phosphorus-containing materials, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3608Bone, e.g. demineralised bone matrix [DBM], bone powder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645Connective tissue
    • A61L27/365Bones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58Materials at least partially resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • A61L2300/604Biodegradation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/02Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
DK16192448.5T 2012-07-19 2013-07-19 Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande DK3175852T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261673514P 2012-07-19 2012-07-19
US201361793929P 2013-03-15 2013-03-15
EP13745254.6A EP2874620B1 (en) 2012-07-19 2013-07-19 Difluorolactam compositions for ep4-mediated osteo related diseases and conditions

Publications (1)

Publication Number Publication Date
DK3175852T3 true DK3175852T3 (da) 2019-05-27

Family

ID=48916211

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16192448.5T DK3175852T3 (da) 2012-07-19 2013-07-19 Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande
DK13745744.6T DK2875022T3 (da) 2012-07-19 2013-07-19 Difluorlactamforbindelser som ep4-receptorselektive agonister til anvendelse ved behandling af ep4-medierede sygdomme og tilstande

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13745744.6T DK2875022T3 (da) 2012-07-19 2013-07-19 Difluorlactamforbindelser som ep4-receptorselektive agonister til anvendelse ved behandling af ep4-medierede sygdomme og tilstande

Country Status (21)

Country Link
US (8) US9180116B2 (da)
EP (4) EP3175852B1 (da)
JP (3) JP6141430B2 (da)
KR (2) KR102131378B1 (da)
CN (4) CN106748951B (da)
AU (3) AU2013292356B2 (da)
CA (2) CA2879506C (da)
CY (1) CY1118929T1 (da)
DK (2) DK3175852T3 (da)
ES (3) ES2728159T3 (da)
HK (2) HK1206016A1 (da)
HR (1) HRP20170045T1 (da)
HU (2) HUE031885T2 (da)
IL (3) IL236637A (da)
LT (1) LT2875022T (da)
NZ (2) NZ704178A (da)
PH (1) PH12015500111A1 (da)
PL (1) PL2875022T3 (da)
PT (2) PT2875022T (da)
SI (1) SI2875022T1 (da)
WO (2) WO2014015247A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2875022T (lt) 2012-07-19 2017-03-10 Cayman Chemical Company, Incorporated Difluorlaktamo junginiai, tokie kaip ep4 receptoriaus selektyvūs agonistai, skirti naudoti ep4 sąlygotų ligų ir būsenų gydymui
AU2014229065B2 (en) * 2013-03-15 2017-03-09 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
SG11201507470WA (en) 2013-03-15 2015-10-29 Cayman Chemical Co Inc Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CN105392505A (zh) 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、系统和组合物
HU231033B1 (hu) 2016-03-22 2019-12-30 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Eljárás 3-as kötést tartalmazó optikailag aktív karbonsavak, karbonsav sók és karbonsav származékok előállítására
CN106699604B (zh) * 2017-01-09 2019-01-01 四川同晟生物医药有限公司 一种沙库比曲及其中间体的制备方法
EP3446661B1 (en) 2017-08-21 2021-12-29 Cook Medical Technologies LLC Braided stent crown geometry and flare

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
ZA747723B (en) * 1974-12-11 1976-11-24 Pfizer 11-desoxy-15-substituted-omega-pentanor prostaglandins
US4154949A (en) 1974-12-11 1979-05-15 Pfizer Inc. 11-Desoxy-15-substituted-ω-pentanor prostaglandins
IT1037126B (it) * 1975-03-14 1979-11-10 Erba Carlo Spa 13.4 deidro ii desossi prosta glandine
DE2517771A1 (de) 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
CA1085859A (en) 1975-06-27 1980-09-16 Wilhelm Bartmann Pyrrolidones and process for their manufacture
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4268522A (en) 1976-06-14 1981-05-19 Pfizer Inc. 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
DE2729960A1 (de) * 1977-06-30 1979-01-18 Schering Ag Neue acetylenprostaglandine und verfahren zu ihrer herstellung
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
JPS58124778A (ja) * 1982-01-20 1983-07-25 Toray Ind Inc 5,6,7−トリノル−4,8−インタ−m−フエニレンPGI↓2誘導体
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
GB8329559D0 (en) * 1983-11-04 1983-12-07 Erba Farmitalia Furyl derivatives of 16-substituted prostaglandins preparations
US5401768A (en) 1987-10-16 1995-03-28 Toray Industries, Inc. 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2, derivative, manufacturing process thereof and its use
JPH0662599B1 (da) * 1987-10-16 1994-08-17 Toray Industries
DE3835162A1 (de) * 1988-10-13 1990-04-19 Schering Ag (1s,2s,3r,5r)-2-((3s)-2-halogen-3-hydroxy-1-alken(inyl))-3-trialkylsilyloxy-7,7-(2,2-dimethyl-trimethylendioxy)-bicyclo-(3.3.0)-octan-verbindungen und verfahren zu deren herstellung
US7229959B1 (en) 1990-11-27 2007-06-12 The American National Red Cross Supplemented fibrin matrix delivery systems
CA2093836A1 (en) 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
JP3388867B2 (ja) 1994-03-31 2003-03-24 株式会社東芝 宛名領域検出装置および宛名領域検出方法
AU1120295A (en) 1994-11-07 1996-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cartilage-derived morphogenetic proteins
US7517539B1 (en) 1996-10-16 2009-04-14 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
US20020098222A1 (en) 1997-03-13 2002-07-25 John F. Wironen Bone paste
ZA984040B (en) 1997-05-15 1998-11-20 Ono Pharmaceutical Co Benzenesulfonamide compounds
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
AU1293101A (en) 1999-12-22 2001-07-03 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
DK1339678T3 (da) * 2000-11-27 2008-02-04 Pfizer Prod Inc Selektive agonister til EP4-receptor til behandling af osteoporose
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
DK1408961T3 (da) 2001-07-16 2007-11-05 Hoffmann La Roche 2 pyrrolidon-derivater som prostanoide agonister
ATE315022T1 (de) 2001-07-16 2006-02-15 Hoffmann La Roche Prostaglandinanaloga als ep4-rezeptoragonisten
CN1863768A (zh) * 2001-07-16 2006-11-15 霍夫曼-拉罗奇有限公司 作为ep4受体激动剂的前列腺素类似物
EP1417975B1 (en) 2001-07-23 2011-03-02 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
CA2463102C (en) 2001-10-23 2011-05-10 Applied Research Systems Ars Holding N.V. Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
AU2002346562A1 (en) * 2001-12-03 2003-06-17 Merck & Co., Inc. Method for treating ocular hypertension
AU2002346561B2 (en) 2001-12-03 2006-08-17 Merck & Co., Inc. EP4 receptor agonist, compositions and methods thereof
PL372084A1 (en) 2002-03-05 2005-07-11 Ono Pharmaceutical Co, Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
CA2479222A1 (en) 2002-03-18 2003-09-25 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
EP1487437B1 (en) 2002-03-18 2006-08-16 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of diseases
US7326426B2 (en) 2002-03-29 2008-02-05 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable liquid polymers
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2003103604A2 (en) 2002-06-01 2003-12-18 Applied Research Systems Ars Holding N.V Gamma lactams as prostaglandin agonists and use thereof
EP1513589B1 (en) 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
WO2004037786A2 (en) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. 2-pyrrolidones as ep4 receptor agonists
JP4582456B2 (ja) 2003-01-21 2010-11-17 小野薬品工業株式会社 8−アザプロスタグランジン誘導体およびその医薬用途
US7276531B2 (en) * 2003-03-03 2007-10-02 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US7163920B2 (en) 2003-09-30 2007-01-16 Ethicon, Inc. Peptide with osteogenic activity
US20070191319A1 (en) 2003-12-17 2007-08-16 Pfizer Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
JPWO2006016695A1 (ja) 2004-08-10 2008-05-01 小野薬品工業株式会社 Ep4アゴニストを含有してなる高カリウム血症の予防および/または治療剤
WO2006016689A1 (ja) 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤
US20060039949A1 (en) 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060057184A1 (en) 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
US7621963B2 (en) 2005-04-13 2009-11-24 Ebi, Llc Composite bone graft material
KR101465994B1 (ko) 2005-05-27 2014-11-27 로이어 바이오메디칼 인코포레이티드 생체재흡수성 중합체 매트릭스 및 이의 제조방법과 사용방법
AU2006287478B2 (en) 2005-09-09 2012-02-02 Agnovos Healthcare, Llc Composite bone graft substitute cement and articles produced therefrom
KR20060013354A (ko) 2005-12-09 2006-02-09 (주)코리아 본 뱅크 인산칼슘계 시멘트 첨가에 의해 개질된 탈회골 기질의 개발
US20070232660A1 (en) 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2008136519A1 (ja) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Ep4アゴニストを含有してなる細胞傷害性t細胞の活性化剤
WO2009023193A1 (en) * 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
NZ585103A (en) 2007-10-23 2012-04-27 Allergan Inc Substituted lactams derivatives and their uses for glaucoma and ocullar hypertension
US20090112332A1 (en) 2007-10-31 2009-04-30 Alexis Paul Shelokov Bone graft and bone graft substitutes with antibiotics for sustained, localized release of antibiotics for reducing postoperative surgical wound infection in spinal and other bone surgery
US8685432B2 (en) 2008-03-25 2014-04-01 University Of Utah Research Foundation Controlled release tissue graft combination biomaterials
WO2011127149A1 (en) 2010-04-06 2011-10-13 University Of Utah Research Foundation Controlled release combination biomaterials
AU2009236216B2 (en) 2008-04-15 2015-05-21 Life Science Enterprises, Inc. Minimally invasive treatment of vertebra (MITV) using a calcium phosphate combination bone cement
WO2010011599A2 (en) 2008-07-22 2010-01-28 Osteogenex Inc. Pimethixene derivatives for promoting bone growth
US20100055183A1 (en) 2008-08-28 2010-03-04 Osteogenex Inc. Trimeprazine and ethopropazine derivatives for promoting bone growth
US9320761B2 (en) 2008-12-18 2016-04-26 Vivex Biomedical, Inc. Bone induction system and methods
US20120270934A1 (en) 2009-07-03 2012-10-25 Concert Pharmaceuticals, Inc. Prostacyclin derivatives
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
EP2638008B1 (en) 2010-11-10 2015-07-01 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
EP2640429B1 (en) 2010-11-15 2016-12-21 Zimmer Orthobiologics, Inc. Bone void fillers
US20120283293A1 (en) 2011-05-06 2012-11-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation
EP2740475A4 (en) 2011-08-02 2015-02-25 Ono Pharmaceutical Co ACTIVE AGENT FOR IMPROVING THE LEFT-VENTRICULAR DIASTOLIC FUNCTION
US20170260173A1 (en) 2012-07-19 2017-09-14 Myometrics, Llc Difluorolactam compositions for ep4-mediated osteo related diseases and condtions
LT2875022T (lt) 2012-07-19 2017-03-10 Cayman Chemical Company, Incorporated Difluorlaktamo junginiai, tokie kaip ep4 receptoriaus selektyvūs agonistai, skirti naudoti ep4 sąlygotų ligų ir būsenų gydymui
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
AU2014229065B2 (en) 2013-03-15 2017-03-09 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
SG11201507470WA (en) 2013-03-15 2015-10-29 Cayman Chemical Co Inc Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
CN105392505A (zh) 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、系统和组合物
WO2017022045A1 (ja) 2015-08-03 2017-02-09 株式会社sizebook 携帯情報装置、寸法測定方法、および寸法測定プログラム

Also Published As

Publication number Publication date
IL236636A (en) 2017-03-30
CN104640542A (zh) 2015-05-20
KR102131378B1 (ko) 2020-07-08
IL250725A0 (en) 2017-04-30
CN107802623A (zh) 2018-03-16
CY1118929T1 (el) 2018-01-10
CN104583201A (zh) 2015-04-29
EP3175852A1 (en) 2017-06-07
CA2879506A1 (en) 2014-01-23
WO2014015246A1 (en) 2014-01-23
WO2014015247A1 (en) 2014-01-23
US20200207709A1 (en) 2020-07-02
IL236637A (en) 2016-04-21
AU2017200044B2 (en) 2018-12-13
US9180116B2 (en) 2015-11-10
US9487478B2 (en) 2016-11-08
US11066361B2 (en) 2021-07-20
JP2017160237A (ja) 2017-09-14
EP3176162A1 (en) 2017-06-07
AU2017200044A1 (en) 2017-02-02
HRP20170045T1 (hr) 2017-03-10
US9440919B2 (en) 2016-09-13
HK1206016A1 (en) 2015-12-31
US10556862B2 (en) 2020-02-11
ES2610428T3 (es) 2017-04-27
PH12015500111A1 (en) 2015-03-30
CN104640542B (zh) 2017-09-22
HUE031190T2 (en) 2017-06-28
ES2612921T3 (es) 2017-05-19
IL236637A0 (en) 2015-02-26
AU2013292357B2 (en) 2017-02-02
DK2875022T3 (da) 2017-01-23
EP2874620B1 (en) 2016-10-12
CA2879507A1 (en) 2014-01-23
CN104583201B (zh) 2016-12-14
US20150175538A1 (en) 2015-06-25
KR102151578B1 (ko) 2020-09-03
JP6141430B2 (ja) 2017-06-07
US20170066751A1 (en) 2017-03-09
LT2875022T (lt) 2017-03-10
JP2015522623A (ja) 2015-08-06
US20150174099A1 (en) 2015-06-25
PT3175852T (pt) 2019-06-04
EP2874620A1 (en) 2015-05-27
US20190092722A1 (en) 2019-03-28
AU2013292356A1 (en) 2015-02-19
CN107802623B (zh) 2020-10-30
CN106748951B (zh) 2020-07-24
US11884624B2 (en) 2024-01-30
JP2019163300A (ja) 2019-09-26
NZ704178A (en) 2017-08-25
US9701630B2 (en) 2017-07-11
AU2013292357C1 (en) 2017-05-25
EP3176162B1 (en) 2020-05-27
US20230050318A1 (en) 2023-02-16
EP2875022B1 (en) 2016-10-12
IL236636A0 (en) 2015-02-26
AU2013292356B2 (en) 2018-02-01
US20160340306A1 (en) 2016-11-24
IL250725B (en) 2019-01-31
AU2013292357A1 (en) 2015-02-19
ES2728159T3 (es) 2019-10-22
EP2875022A1 (en) 2015-05-27
NZ704171A (en) 2017-10-27
KR20150036651A (ko) 2015-04-07
US20160024006A1 (en) 2016-01-28
CN106748951A (zh) 2017-05-31
HK1205937A1 (en) 2015-12-31
HUE031885T2 (en) 2017-08-28
PT2875022T (pt) 2016-12-22
PL2875022T3 (pl) 2017-06-30
JP6766008B2 (ja) 2020-10-07
KR20150036652A (ko) 2015-04-07
SI2875022T1 (sl) 2017-04-26
EP3175852B1 (en) 2019-03-06
CA2879506C (en) 2020-10-27

Similar Documents

Publication Publication Date Title
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
SMT201700065B (it) Derivato piridonico
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2763665T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK2884999T3 (da) Fremgangsmåde og sammensætninger til cellulær immunterapi
DK3080274T3 (da) Fremgangsmåder og sammensætninger til genom-manipulation
DK2857401T3 (da) Hidtil ukendt -lactamaseinhibitor og fremgangsmåde til at fremstille samme
BR112015003354A2 (pt) composições e métodos de microcápsula
DK3354728T3 (da) Alpha-amylase-varianter
DK2911506T3 (da) Driftreducerende sammensætninger
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2768479T3 (da) Hjælpestoffer til nikotin-indeholdende terapeutiske sammensætninger
DK2928921T3 (da) Sammensætninger og fremgangsmåder til antistoffer målrettet epo
DK2861223T3 (da) Sammensætninger og metoder til transmukosal absorption
BR112014032798A2 (pt) composição
BR112015001562A2 (pt) biotinas e composições
DK2908661T3 (da) Mikroalgemelgranulater og fremgangsmåde til fremstilling deraf
DK3175852T3 (da) Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
DK2897594T3 (da) Farmaceutisk sammensætning
DK2896694T3 (da) Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf
FR2993777B1 (fr) Composition photo-protectrice